Replies to post #27400 on Marker Therapeutics Inc (MRKR)

[staccani]

Cytokine release is out of question and in general excellent safety profile has been confirmed with many patients in blood cancers.

Now , regardless of epitote spreading what we want to see is ORR and PFS results. This because solid tumors immunosuppressive microenvironment is very different from hematological tumors and at the moment we do not know if what works in blood cancers can produce meaningful clinical benefits also in solid tumors. A plenary oral presentation at an important medical conference followed by a company coneference call (management has to wake up in the middle of the night to do a conference call at 8.30 Eastern time on Monday) leads me to believe they have at least some interesting results to show.